[
  {
    "ts": null,
    "headline": "Incyte (INCY) Is Up 11.9% After Phase 3 frontMIND Success in First-Line High-Risk DLBCL",
    "summary": "Incyte recently reported positive topline results from its pivotal Phase 3 frontMIND trial, where adding tafasitamab (Monjuvi/Minjuvi) and lenalidomide to R-CHOP improved progression-free survival for newly diagnosed high-risk diffuse large B-cell lymphoma patients without new safety issues. This strengthens the case for tafasitamab as a potential first-line option in a major lymphoma indication, pending planned regulatory filings in 2026. We’ll now examine how the successful frontMIND Phase...",
    "url": "https://finnhub.io/api/news?id=6e7563852584f6b1d6af5b5acf63e5fd4790530a826f584d059cc4f99081d673",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767856370,
      "headline": "Incyte (INCY) Is Up 11.9% After Phase 3 frontMIND Success in First-Line High-Risk DLBCL",
      "id": 138033880,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte recently reported positive topline results from its pivotal Phase 3 frontMIND trial, where adding tafasitamab (Monjuvi/Minjuvi) and lenalidomide to R-CHOP improved progression-free survival for newly diagnosed high-risk diffuse large B-cell lymphoma patients without new safety issues. This strengthens the case for tafasitamab as a potential first-line option in a major lymphoma indication, pending planned regulatory filings in 2026. We’ll now examine how the successful frontMIND Phase...",
      "url": "https://finnhub.io/api/news?id=6e7563852584f6b1d6af5b5acf63e5fd4790530a826f584d059cc4f99081d673"
    }
  },
  {
    "ts": null,
    "headline": "2 Cash-Heavy Stocks Worth Investigating and 1 Facing Challenges",
    "summary": "A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.",
    "url": "https://finnhub.io/api/news?id=cf6254cb947a3e0fcc247aaa403116bd84304308dbd7f680de069648a43c4141",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767847095,
      "headline": "2 Cash-Heavy Stocks Worth Investigating and 1 Facing Challenges",
      "id": 138035138,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.",
      "url": "https://finnhub.io/api/news?id=cf6254cb947a3e0fcc247aaa403116bd84304308dbd7f680de069648a43c4141"
    }
  }
]